Continuous Renal Replacement Therapy Industry Overview

The global continuous renal replacement therapy market size was valued at USD 1,356.7 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 8.6% from 2023 to 2030.

Rising incidence of acute kidney injury (AKI), increasing incidence of sepsis, rapid increase in the volume of hospitals and urgent care centers, growing hospital admissions rate, and constant product launches by prominent market players are a few factors driving the demand for CRRT, thereby propelling the market growth. According to the American Kidney Fund, 37 million U.S. citizens are living with kidney disease and 807,000 people in the U.S. are diagnosed with kidney failure.

Gather more insights about the market drivers, restrains and growth of the Continuous Renal Replacement Therapy Market

In the pre-COVID-19 era, the burden of COVID-19-associated AKI climbed to almost 4 million cases per year. CRRT was utilized to treat roughly 23,105 AKI patients per year prior to COVID-19. The need for CRRT appeared to be 5 times higher in COVID-19 patients, i.e., 4.9 percent, than in historical populations (0.9 percent). In community cohort datasets, 5%–15% of people hospitalized with COVID-19 needed dialysis. Moreover, in some North America regions, the number of people utilizing CRRT jumped by 370 percent over normal levels due to which the demand for the product increased during the pandemic. For instance, Fresenius Medical Care North America's Renal Therapies Group (FMCNA) released the first batch of multiBic dialysate solutions to U.S. hospitals in May 2020, according to an FDA emergency use authorization. These medicines were intended to provide CRRT to COVID-19-related individuals with acute renal failure.

Furthermore, the pandemic also led to a surge in demand for CRRT worldwide. As a result, the market for continuous renal replacement therapy witnessed an increase in financial incentives as well as regulatory support from various government agencies. In addition, the FDA imposed tight regulations requiring manufacturers to ensure the availability of high-quality CRRT devices in intensive care units.

The increased demand for advanced CRRT devices as a result of improved patient outcomes is a high-impact major driver of the market for continuous renal replacement therapy. The current CRRT technology has made it possible to analyze and respond to technical data in a complete manner. These improvements have resulted in a detailed examination of prescription and delivery patterns, which has had a favorable impact on clinical results from the standpoint of quality assurance. The most recent CRRT machines allow automated data gathering and uniform language, allowing for cross-institutional comparisons. Several major market manufacturers have introduced sophisticated CRRT machines that use these technologies, which is expected to boost the growth of the market.

Furthermore, the development of improved pediatric CRRT products is projected to the market for continuous renal replacement therapy in the near future. Pediatric patients who require CRRT have traditionally been treated with systems that are created and indicated for adults and are not licensed for pediatric usage, which can lead to clinical problems in neonates. As a result, various manufacturers currently offer a range of renal care solutions that enhance access to care, results, and quality of life for patients with severe renal disease or injury anywhere in the globe, regardless of their size or age, which is projected to fuel market expansion.

According to American Hospital Association in 2023, there were 5,157 community hospitals, 206 federal government hospitals, and 107 other hospitals in the U.S. In addition, the significant increase in the number of hospital admissions for AKI along with the increasing geriatric population is boosting the demand for CRRT systems, thereby propelling market growth. Moreover, according to the Centers for Disease Control and Prevention in 2021, nearly 786,000 people in the U.S. were living with ESKD, also known as end-stage renal disease (ESRD), with 71% on dialysis and 29% with a kidney transplant. As of 2020, there were around 7,500 dialysis clinics in the U.S.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global radiation dose monitoring market size was valued at USD 3.44 billion in 2023 and is projected to grow at a CAGR of 6.3% from 2024 to 2030.
• The global patient monitoring accessories market sizewas valued at USD 7.83 billion in 2023 and is projected to grow at a CAGR of 9.0% from 2024 to 2030. 

Continuous Renal Replacement Therapy Market Segmentation

Grand View Research has segmented the global continuous renal replacement therapy market on the basis of product, modality, and region:

Continuous Renal Replacement Therapy Product Outlook (Revenue, USD Million, 2018 - 2030)

• System
• Consumables

Continuous Renal Replacement Therapy Modality Outlook (Revenue, USD Million, 2018 - 2030)

• Slow Continuous Ultra-Filtration (SCUF)
• Continuous Venovenous Hemofiltration (CVVH)
• Continuous Venovenous Hemodialysis (CVVHD)
• Continuous Venovenous Hemodiafiltration (CVVHDF)

Continuous Renal Replacement Therapy Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • U.S.
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Norway
  • Denmark
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Kuwait

Key Companies profiled:

• Braun Melsungen AG
• Baxter International, Inc.
• Fresenius Medical Care AG Co. KGaA
• Asahi Kasei Corporation
• NIPRO Corporation
• Toray Medical Co., Ltd
• NxStage Medical, Inc.
• Medtronic PLC

Order a free sample PDF of the Continuous Renal Replacement Therapy Market Intelligence Study, published by Grand View Research.